Skip to main content

Clinical Trials Using Azacitidine

Review the clinical trials studying azacitidine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 89

Olutasidenib in Combination with Hypomethylation Therapy for the Treatment of IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine Plus Venetoclax for the Treatment of AML That is Relapsed or Refractory to Venetoclax and a Hypomethylating Agent
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Olutasidenib with Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients with Prior Treatment with Venetoclax plus a Hypomethylating Agent
Status: Active
Location: 5 locations
Azacitidine and Pembrolizumab for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine, Low Dose Cytarabine, Venetoclax, and Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome/Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ivosidenib or Enasidenib plus Azacitidine followed by Venetoclax plus Azacitidine compared to Venetoclax plus Azacitidine followed by Ivosidenib or Enasidenib plus Azacitidine for the Treatment of IDH Mutated Acute Myeloid Leukemia, I-DATA Trial
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Nadunolimab and Azacitidine With or Without Venetoclax for the Treatment of Patients with Myelodysplastic Syndrome or Relapsed or Refractory Acute Myelogenous Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pacritinib in Combination with Azacitidine for the Treatment of Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Investigating Novel Therapies for the Treatment of Acute Myeloid Leukemia Patients with Rising Measurable Residual Disease and/or Morphological Relapse, ALLG AMLM26 INTERCEPT Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients with Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ziftomenib, Venetoclax, and Azacitidine for the Treatment of Pediatric Patients with Relapsed and Refractory Acute Leukemias
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intrathecal Azacitidine and Nivolumab for the Treatment of Patients with Recurrent High-Grade Glioma
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Imetelstat and Azacitidine with or without Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, IMAGINE Trial
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients with CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Iadademstat in Combination with Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Rezatapopt in Combination with Azacitidine with or without Venetoclax for the Treatment of TP53Y220C Mutant Relapsed, Refractory or Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ruxolitinib in Combination with Venetoclax with and without Azacitidine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 3 locations
Azacitidine and Decitabine for the Treatment of Myelodysplastic Syndrome or Other Related Cancers
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Azacitidine for Relapse Prevention in Transplant Eligible Patients with Acute Myeloid Leukemia Not Proceeding to Transplant
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia